Cancer vaccine NY-ESO-1 (PowderMed)

N/A

Report date: 2022/03/17 14:50:05

Base Information

Drug NameCancer vaccine NY-ESO-1 (PowderMed)

Drug Alias NameN/A

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine

Mechanisms of ActionImmunostimulantsAnti-NY-ESO-1

TargetsCancer/testis antigen 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell Lung

ATC CodeN/A